Pliant Therapeutics (PLRX) Non-Current Assets (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Non-Current Assets of $27.7 million for Q1 2026, down 17.61% year-over-year from $33.6 million in Q1 2025, and down 3.87% quarter-over-quarter from $28.8 million in Q4 2025.
Pliant Therapeutics (PLRX) Non-Current Assets (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Non-Current Assets for 8 consecutive years, with $27.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 17.61% year-over-year to $27.7 million; the TTM figure through Mar 2026 stood at $119.8 million (down 14.45% YoY), while the FY2025 annual figure was $28.8 million, down 17.02% from the prior year.
- Non-Current Assets eased to $27.7 million in Q1 2026 per PLRX's latest filing, from $28.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $36.2 million in Q2 2024 and bottomed at $6.1 million in Q3 2023.
- Historically, Non-Current Assets has averaged $21.6 million across 5 years, with a median of $27.7 million in 2026.
- Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 45.35% — and 2024, when it soared 481.4%.
- Pliant Therapeutics' Non-Current Assets stood at $10.3 million in 2022, then sank by 35.43% to $6.7 million in 2023, then jumped by 421.42% to $34.7 million in 2024, then retreated by 17.02% to $28.8 million in 2025, then retreated by 3.87% to $27.7 million in 2026.
- Business Quant data shows PLRX's Non-Current Assets at $27.7 million in Q1 2026, $28.8 million in Q4 2025, and $31.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | 26.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.74 Mn |
| Mar 31, 2026 | 27.67 Mn |
| Dec 31, 2025 | 28.78 Mn |
| Sep 30, 2025 | 31.01 Mn |
| Jun 30, 2025 | 32.38 Mn |
| Mar 31, 2025 | 33.58 Mn |
| Dec 31, 2024 | 34.69 Mn |
| Sep 30, 2024 | 35.63 Mn |
| Jun 30, 2024 | 36.18 Mn |
| Mar 31, 2024 | 31.71 Mn |
| Dec 31, 2023 | 6.65 Mn |
| Sep 30, 2023 | 6.13 Mn |
| Jun 30, 2023 | 9.19 Mn |
| Mar 31, 2023 | 9.65 Mn |
| Dec 31, 2022 | 10.30 Mn |
| Sep 30, 2022 | 11.22 Mn |
| Jun 30, 2022 | 11.09 Mn |
| Mar 31, 2022 | 11.66 Mn |
| Dec 31, 2021 | 11.77 Mn |
| Sep 30, 2021 | 5.54 Mn |